Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollinger-Ellison syndromes: Case series and literature review

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 2, 2010, Pages 246-252

  Said, Rabih ^a   O'Reilly, Eileen M ^b   Blumgart, Leslie ^b   Shia, Jinru ^b   Abou Alfa, Ghassan K ^b  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cushing's syndrome; Embolization; Ketoconazole; Pancreatic islet cell carcinoma; Somatostatin; Zollinger Ellison syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ESOMEPRAZOLE; MEK 0646; OCTREOTIDE; PANTOPRAZOLE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CUSHING SYNDROME; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCORTISOLISM; LABORATORY TEST; LIVER BIOPSY; METASTASIS; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; ULCER; ZOLLINGER ELLISON SYNDROME;

ADRENALECTOMY; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, ISLET CELL; COMBINED MODALITY THERAPY; CUSHING SYNDROME; EMBOLIZATION, THERAPEUTIC; FATAL OUTCOME; FEMALE; GASTROINTESTINAL AGENTS; HORMONE ANTAGONISTS; HUMANS; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; ZOLLINGER-ELLISON SYNDROME;

EID: 75749107903     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283314827     Document Type: Article

References (58)

1. Delcore R, Friesen SR. Gatrointestinal neuroendocrine tumors. J am Coll Surg 1994; 178:187-211.
2. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19:647.
3. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955; 142:709.
4. Ellison EH, Wilson SD. The Zollinger-Ellison syndrome: re-appraisal and evaluation of 260 registered cases. Ann Surg 1964; 160:512-530.
5. Bonfils S, Landor JH, Mignon M, Hervoir P. Results of surgical management in 92 consecutive patients with Zollinger-Ellison syndrome. Ann Surg 1981; 194:692-697.
6. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, Dimagno EP, Gardner JD, Lebenthal E, Reber H, Scheele GA, editors. The pancreas: biology, pathobiology and diseases. 2nd ed. New York: Raven Press. pp. 1993. 931-178.
7. Isenberg JI, Walsh JH, Grossman MI. Zollinger-Ellison syndrome. Gastroenterology 1973; 65:140.
8. Heitz PU, Kasper M, Polak JM, Kloppel G. Pancreatic endocrine tumors. Hum Pathol 1982; 13:263-271.
9. Doppman JLK, Nieman LK, Cutler GB Jr, Chrousos GP, Fraker DL, Norton JA, Jensen RT. Adrenocorticotropic hormone-secreting islet cell tumors: are they always malignant? Radiology 1994; 190:59-64.
10. Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with Zollinger-Ellison syndrome. N Engl J Med 1986; 315:1-5.
11. Amikura K, Norton JA, Doherty GM, Alexander HR, Doppman JL, Venson DJ, et al. Role of surgery in management of adrenocorticotropic hormone-producing islet cell tumors of the pancreas. Surgery 1995; 124:1125-1132.
12. Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmak C, Modlin IM, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-ellisson syndrome. Gastroenterology 2000; 118:696-704.
13. Jensen RT. Gastrinomas: advances in diagnosis and management. Neuroendocrinology 2004; 1:23-27.
14. Frucht H, Maton PN, Jensen RT. Use of omeprasole in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1991; 36:394-404.
15. Desir B, Poitras P. Oral Pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome. Can J Gastroenterol 2001; 15:795-798.
16. Hirschowitz BI, Mohen J, Shaw S. Long-term treatment with lansoprazole in Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1996; 10:507-522.
17. Metz DC, Pisegna JR, Ringham GL, Feigenbaum K, Koviack PD, Maton PN, et al. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci 1993; 38:245-256. (Pubitemid 23054357)
18. Carswell CI, Goa KL. Rabeprazole: an update of its use in acid-related disorders. Drugs 2001; 61:2327-2356.
19. Ross NS. Epidemiology of Cushing's syndrome and subclinical disease. Endocrinol Metab Clin North Am 1994; 23:539-546.
20. Sonino N, Boscaro M, Paoletta A, Mantero F, Zilotto D. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 1991; 35:347-352.
21. Engelhardt D, Weber MM. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 1994; 49:261-267. (Pubitemid 24240610)
22. Hoffman DM, Brigham B. The use of ketoconazole in ectopic adrenocorticotropic hormone syndrome. Cancer 1991; 67:1447-1449.
23. Kornely E, Schlaghecke R, Horster FA. Palliative therapy of an ectopic cushing's syndrome due to a metastatic carcinoid tumor. Klin Wochenscher 1991; 69:173-176.
24. Farwell AP, Devlin JT, Stewart JA. Total suppression of cortisol excretion by ketoconazole in the therapy of the ectopic adrenocorticotropic hormone syndrome. Am J Med 1988; 84:1063-1066.
25. Winquist EW, Laskey J, Crump M, Khamsi F, Shepherd FA. Ketoconazole in the management of paraneoplastic cushing's syndrome secondary to ectopic adrenocorticotropin production. J Clin Oncol 1995; 13:157-164.
26. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues. Digestion 2000; 62 (Suppl 1):84-91.
27. Ruszniewski P, Laucournet H, Elouaer-Blanc L, Mignon M, Bonfils S. Longacting somatostatin (SMS 201-995) in the management of Zollinger-Ellison syndrome: evidence of sustained efficacy. Pancreas 1988; 3:145-152.
28. Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. Treatment of type II gastric carcinoid tumors wih somatostatin analogues. N Engl J Med 2000; 343:551-554.
29. Saltz L, Trochanowsky G, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, Kelsen D. Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumours. Cancer 1993; 72:244-248.
30. Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer 1996; 77:402-408.
31. Arnold R, Trautmann ME, CreutzfeldtW, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumors. Gut 1996; 38:430-438.
32. Faiss S, Rath U, Mansmann U, Caird D, Clemens N, Riecken EO, Wiedenmann B. Ultra high dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumours. Digestion 1999; 60:469-476.
33. Erikkson B, Renstrup J, Iman H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997; 8:1041-1044.
34. Faiss S, Pape UF, Bohmig M, Dorffe Y, Mansmann U, Golder W, et al. Prospective, Randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastropancreatic tumors- the international lantreotide and interferon alfa study group. J Clin Oncol 2003; 21:2689-2696.
35. Vinik AI, Tsai S, Moattri AR, Cheung P. Somatostatin analogue (SMS-201-995) in patients with gastrinomas. Surgery 1988; 104: 834-842.
36. Mozell EJ, Cramer AJ, O'Dorisio TM, Woltering EA. Long-term efficacy of octreotide in the treatment of Zollinger-Ellison syndrome. Arch Surg 1992; 127:1019-1024.
37. Gaztambide S, Vasquez JA. Short- and long-term effect of a long-acting somatostatin analogue, lanreotide on metastatic gastrinoma. J Endocrinol Invest 1999; 22:144-146.
38. Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002; 94:331-343.
39. Oberg K. Interferon in the management of neuroendocrine GEP-tumors. Digestion 2000; 62 (Suppl 1):92-97.
40. Pisegna JR, Slimak GG, Doppman JL, Strader DB, Metz C, Benya RV, et al. An elevation of human recombinant alpha interferon in patients with metastatic gastrinoma. Gastrenterology 1993; 105:1179-1183.
41. Eriksson B, Oberg K, Alm G, Karlsson A, Lundqvist G, Anderson T, et al. Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Lancet 1986; 2:1307-1309. (Pubitemid 17177866)
42. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71:2624-2630.
43. Stokes KR, Stuart K, Clouse ME. Hepatic arterial chemoembolization for metastatic endocrine tumors. J Vasc Interv Radiol 1993; 4:341-345.
44. Skinazi F, Zins M, Menu Y, Bernades P, Ruszniewski P. Eur J Gasterol Hepatol 1996; 8:673-678.
45. Ruutianinen AT, Soulen MC, Tuite CM, Clark TW, Mondschein JI, Stavropoulos SW, Trerotola SO. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 2007; 18:847-855.
46. Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M. D. Anderson experience. Cancer J 2003; 9:261-267.
47. Sofocleous C, Petre E, Gonen M, Saltz L, Covey A, Thornton R, et al. Management of hepatic neuroendocrine metastases with bland hepatic arterial embolization. J Vasc Interv Radiol 2008; 19:24.
48. Strosberg J, Choi J, Cantor A, Kvols L. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006; 13:72-78.
49. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestio 2000; 62:73-78.
50. O'Toole D, Hentie O, Corcos O, Rusziewski P. Chemotherapy for gastro-enteropancreatic endocrine tumors. Neuroendocrinology 2004; 80:79-84.
51. Von Schrenck T, Howard JM, Doppman JL, Norton JA, Maton PN, Smith FP, et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 1998; 94:1326-1334.
52. Ruzszniewski P, Hochlaf S, Rougier P, Mignon M. Intravenous chemotherapy with streptozotocin and 5 fluorouracil for hepatic metastases of Zollinger- Ellison syndrome. A prospective multicenter study in 21 patients. Gastroenterol Clin Biol 1991; 15:393-398.
53. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68:227-232.
54. Lee JE, Park HS, Jung SS, Kim JO, Kim SY. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer. Oncology 2007; 73:76-80 [Epub ahead of print 12 Mar 2008]
55. Ferrari L, Delta TS, Collini P, Martinetti A, Procopio G, De DS, et al. Kit protein and proliferation index in evaluation in well and poorly differentiated neuroendocrine tumors. Tumori 2006; 92:531-535.
56. Pa Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005; 18:1329-1335.
57. Gilbert JA, Lloyd RV, Ames MM. Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. N Engl J Med 2005; 353:209-210.
58. Hopfner M, Sutter AP, Grest B, Zeitz M, Scherubl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib. Br J Cancer 2003; 89:1766-1775.